Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.76 |
| ▸ | FAP | Q12884 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425528 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL15948742 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL20470307 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL23425531 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL23425530 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL20470082 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL24722481 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL29828516 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL29828277 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2D6 | |
| SCHEMBL23425534 | 0.86 | CYP3A4 (0.78) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020410-B2 | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020410-B2 | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof | PYGL, HPGDS, PAICS | CYP3A4 58/4885CYP2D6 169/4885FAP 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.